Wuhan YZY Biopharma Co Ltd
Wuhan YZY Biopharma Co Ltd Fundamental Analysis
Wuhan YZY Biopharma Co Ltd (2496.HK) shows weak financial fundamentals with a PE ratio of -10.25, profit margin of -70.66%, and ROE of 8.43%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 46.3/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 2496.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2496.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent2496.HK trades at attractive valuation levels.
Growth Score
Weak2496.HK faces weak or negative growth trends.
Financial Health Score
Moderate2496.HK shows balanced financial health with some risks.
Profitability Score
Weak2496.HK struggles to sustain strong margins.
Key Financial Metrics
Is 2496.HK Expensive or Cheap?
P/E Ratio
2496.HK trades at -10.25 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 2496.HK's PEG of -0.79 indicates potential undervaluation.
Price to Book
The market values Wuhan YZY Biopharma Co Ltd at -25.56 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -11.34 times EBITDA. This is generally considered low.
How Well Does 2496.HK Make Money?
Net Profit Margin
For every $100 in sales, Wuhan YZY Biopharma Co Ltd keeps $-70.66 as profit after all expenses.
Operating Margin
Core operations generate -72.70 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $8.43 in profit for every $100 of shareholder equity.
ROA
Wuhan YZY Biopharma Co Ltd generates $-28.56 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Wuhan YZY Biopharma Co Ltd generates limited operating cash flow of $-9.07M, signaling weaker underlying cash strength.
Free Cash Flow
Wuhan YZY Biopharma Co Ltd generates weak or negative free cash flow of $-9.56M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.05 in free cash annually.
FCF Yield
2496.HK converts -1.36% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-10.25
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.79
vs 25 benchmark
P/B Ratio
Price to book value ratio
-25.56
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.25
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-5.71
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.92
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
8.43
vs 25 benchmark
ROA
Return on assets percentage
-0.29
vs 25 benchmark
ROCE
Return on capital employed
-2.59
vs 25 benchmark
How 2496.HK Stacks Against Its Sector Peers
| Metric | 2496.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -10.25 | 28.31 | Better (Cheaper) |
| ROE | 842.97% | 699.00% | Excellent |
| Net Margin | -70.66% | -130884.00% (disorted) | Weak |
| Debt/Equity | -5.71 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 0.92 | 2775.16 | Weak Liquidity |
| ROA | -28.56% | -14469.00% (disorted) | Weak |
2496.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Wuhan YZY Biopharma Co Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation